EUVIMEDEUVIMED entdecken
Crossref

Cyclic Peptide Keap1–Nrf2 Protein–Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury

Jihua Zou, Jianyu Yan, Yifei Lu, Zhou Yu, Kai Zhang, Qianyu Han, Dan Han, Conghao Gai, Xiaoyun Chai iD, Qingjie Zhao, Chunlin Zhuang iD, Yan Zou

Journal of Medicinal Chemistry · 28.03.2024 · 67 (6) · 4889-4903

DOI: 10.1021/acs.jmedchem.4c00065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.03.2024. Verfasst von Jihua Zou und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, PR China. Hauptthemen laut MEDLINE: Peptides, Cyclic, Acute Lung Injury. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Second Military Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Directly blocking the Keap1-Nrf2 pathway is a promising strategy for the mitigation of acute lung injury (ALI). Peptide Keap1-Nrf2 inhibitors have been reported to have a high Keap1 binding affinity. However, these inhibitors showed weak activity in cells and/or animals. In this study, we designed a series of linear peptides from an Nrf2-based 9-mer Ac-LDEETGEFL-NH2. To improve the cellular activity, we further designed cyclic peptides based on the crystal complex of Keap1 with a linear peptide. Among them, cyclic 9-mer ZC9 targeting Keap1 showed a better affinity (KD2 = 51 nM). Specifically, it exhibited an acceptable water solubility (>38 mg/mL), better cell permeability, cell activity, and metabolic stability (serum t1/2 > 24 h). In the in vitro LPS-induced oxidative damages and ALI model, ZC9 showed significant dose-response reversal activity without apparent toxicity. In conclusion, our results suggested ZC9 as a lead cyclic peptide targeting the Keap1-Nrf2 pathway for ALI clinical treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptides, CyclicAcute Lung InjuryAnimalsKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Peptides

Substanzen

Peptides, CyclicKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Peptides

Autor:innen und Institutionen

  • School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, PR China.
  • School of Pharmacy, Second Military Medical University, Shanghai 200433, PR China.
  • Department of Thoracic Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200433, PR China.

ORCID-Profile: Xiaoyun Chai, Chunlin Zhuang

Förderung

  • National Key Research and Development Program of China
  • Second Military Medical University
  • National Natural Science Foundation of China
  • Shanghai Shuguang Program

Zitieren

APA

Zou, J., Yan, J., Lu, Y., Yu, Z., Zhang, K., Han, Q., Han, D., Gai, C., Chai, X., Zhao, Q., Zhuang, C., & Zou, Y. (2024). Cyclic Peptide Keap1–Nrf2 Protein–Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury. Journal of Medicinal Chemistry, 67(6), 4889-4903. https://doi.org/10.1021/acs.jmedchem.4c00065

Vancouver

Zou J, Yan J, Lu Y, Yu Z, Zhang K, Han Q, et al. Cyclic Peptide Keap1–Nrf2 Protein–Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury. Journal of Medicinal Chemistry. 2024;67(6):4889-4903. doi:10.1021/acs.jmedchem.4c00065

BibTeX
@article{Zou2024,
  author = {Zou, Jihua and Yan, Jianyu and Lu, Yifei and Yu, Zhou and Zhang, Kai and Han, Qianyu and Han, Dan and Gai, Conghao and Chai, Xiaoyun and Zhao, Qingjie and Zhuang, Chunlin and Zou, Yan},
  title = {Cyclic Peptide Keap1–Nrf2 Protein–Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {6},
  pages = {4889--4903},
  doi = {10.1021/acs.jmedchem.4c00065}
}
Kostenlos starten →